Background/Aims: Dysphagia, a symptom of multiple system atrophy (MSA), is a major clinical concern. In this study, we investigate the characteristics of early oropharyngeal dysphagia (OD) in patients with MSA, and the differences between MSA subtypes. Methods: Patients enrolled in the study had previously been diagnosed with MSA at the clinic of the Department of Neurology, and had been referred for a videofluoroscopic swallowing study (VFSS), between 2005 and 2014, to check for dysphagia. The clinical characteristics and VFSS findings were analyzed and compared between the MSA subtypes. Results: This study enrolled 59 patients with MSA (24 men; 31 with MSA-P, 21 with MSA-C, and 7 with MSA-PC). Dysphagia symptoms were mostly limited to aspiration symptoms (90.48%) in patients with MSA-C, while difficulty in swallowing, increased mealtime, and drooling were frequent in those with MSA-P. The most common VFSS finding amongst patients was vallecular residue (n = 53, 89.8%), followed by penetration/aspiration (n = 40, 67.8%), and coating of the pharyngeal wall (n = 39, 66.1%). Comparison analysis between subtypes showed that apraxia and vallecular residue were more frequent and severe in MSA-P than in MSA-C (p = 0.033 and p = 0.010, respectively). Conclusion: Understanding early OD characteristics in patients with MSA and the differences between MSA subtypes could be helpful in managing dysphagia in patients with MSA. Several dysphagia symptoms similar to those of Parkinson disease were frequently observed in MSA-P, but not in MSA-C. A follow-up study is needed to elucidate the natural course of OD in MSA patients and the difference between MSA subtypes.

Journal Section:
Original Paper
Keywords:
Multiple system atrophy, Dysphagia, Deglutition, Neurodegenerative diseases
1.
Stefanova N, Bücke P, Duerr S, Wenning GK: Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172–1178.
[PubMed]
https://doi.org/10.1016/S1474-4422(09)70288-1
2.
Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP: Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997; 12: 133–147.
[PubMed]
https://doi.org/10.1002/mds.870120203
3.
Tobergte DR, Curtis S: Progression of dysarthria and dysphagia in postmortem-confirmed Parkinsonian disorders. J Chem Inf Model 2013; 53: 1689–1699.
[PubMed]
https://doi.org/10.1021/ci400128m
4.
Alfonsi E, Versino M, Merlo IM, Pacchetti C, Martignoni E, Bertino G, et al: Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. Neurology 2007; 68: 583–589.
[PubMed]
https://doi.org/10.1212/01.wnl.0000254478.46278.67
5.
Köllensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, et al: Red flags for multiple system atrophy. Mov Disord 2008; 23: 1093–1099.
[PubMed]
https://doi.org/10.1002/mds.21992
6.
Higo R, Tayama N, Watanabe T, Nitou T, Takeuchi S: Vocal fold motion impairment in patients with multiple system atrophy: evaluation of its relationship with swallowing function. J Neurol Neurosurg Psychiatry 2003; 74: 982–984.
[PubMed]
https://doi.org/10.1136/jnnp.74.7.982
7.
Higo R, Nito T, Tayama N: Swallowing function in patients with multiple-system atrophy with a clinical predominance of cerebellar symptoms (MSA-C). Eur Arch Otorhinolaryngol 2005; 262: 646–650.
[PubMed]
https://doi.org/10.1007/s00405-004-0883-0
8.
Higo R, Tayama N, Watanabe T, Nitou T, Ugawa Y: Videofluoroscopic and manometric evaluation of swallowing function in patients with multiple system atrophy. Ann Otol Rhinol Laryngol 2003; 112: 630–636.
[PubMed]
https://doi.org/10.1177/000348940311200710
9.
Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al: Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–676.
[PubMed]
https://doi.org/10.1111/ane.12669
10.
Kim J, Oh BM, Kim JY, Lee GJ, Lee SA, Han TR: Validation of the videofluoroscopic dysphagia scale in various etiologies. Dysphagia 2014; 29: 438–443.
[PubMed]
https://doi.org/10.1007/s00455-014-9524-y
11.
Jung SH, Lee KJ, Hong J-B, Han TRH: Validation of clinical dysphagia scale: based on videofluoroscopic swallowing study. J Korean Acad Rehab Med 2005; 29: 343–350.
12.
Han TR, Paik NJ, Park JW, Kwon BS: The prediction of persistent dysphagia beyond six months after stroke. Dysphagia 2008; 23: 59–64.
[PubMed]
https://doi.org/10.1007/s00455-007-9097-0
13.
Kim DH, Choi KH, Kim HM, Koo JH, Kim BR, Kim TW, et al: Inter-rater reliability of videofluoroscopic dysphagia scale. Ann Rehabil Med 2012; 36: 791–796.
[PubMed]
https://doi.org/10.5535/arm.2012.36.6.791
14.
Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL: A penetration-aspiration scale. Dysphagia 1996; 11: 93–98.
[PubMed]
https://doi.org/10.1007/BF00417897
15.
Daniels SK: Swallowing apraxia: a disorder of the praxis system? Dysphagia 2000; 15: 159–166.
[PubMed]
https://doi.org/10.1007/s004550010019
16.
Uluduz D, Ertürk Ö, Kenangil G, Özekmekçi S, Ertan S, Apaydin H, et al: Apraxia in Parkinson’s disease and multiple system atrophy. Eur J Neurol 2010; 17: 413–418.
[PubMed]
https://doi.org/10.1111/j.1468-1331.2009.02905.x
17.
Ozsancak C, Auzou P, Dujardin K, Quinn N, Destée A: Orofacial apraxia in corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy and Parkinson’s disease. J Neurol 2004; 251: 1317–1323.
[PubMed]
https://doi.org/10.1007/s00415-004-0530-0
18.
Cichero J: Improving swallowing function: compensation; in Cichero J, Murdoch B (eds): Dysphagia: Foundation, Theory and Practice. Chichester, Jon Wiley & Sons, 2006.
19.
Suttrup I, Warnecke T: Dysphagia in Parkinson’s disease. Dysphagia 2016; 31: 24–32.
[PubMed]
https://doi.org/10.1007/s00455-015-9671-9
20.
Muñoz E, Iranzo A, Rauek S, Lomeña F, Gallego J, Ros D, et al: Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C). J Neurol 2011; 258: 2248–2253.
[PubMed]
https://doi.org/10.1007/s00415-011-6108-8
21.
Nagaya M, Kachi T, Yamada T, Sumi Y: Videofluorographic observations on swallowing in patients with dysphagia due to neurodegenerative diseases. Nagoya J Med Sci 2004; 67: 17–23.
[PubMed]
22.
Malandraki GA, Sutton BP, Perlman AL, Karampinos DC, Conway C: Neural activation of swallowing and swallowing-related tasks in healthy young adults: an attempt to separate the components of deglutition. Hum Brain Mapp 2009; 30: 3209–3226.
[PubMed]
https://doi.org/10.1002/hbm.20743
23.
Suzuki M, Asada Y, Ito J, Hayashi K, Inoue H, Kitano H: Activation of cerebellum and basal ganglia on volitional swallowing detected by functional magnetic resonance imaging. Dysphagia 2003; 18: 71–77.
[PubMed]
https://doi.org/10.1007/s00455-002-0088-x
24.
Ramio-Torrentia L, Gomez E, Genis D: Swallowing in degenerative ataxias. J Neurol 2006; 253: 875–881.
[PubMed]
https://doi.org/10.1007/s00415-006-0122-2
25.
Kim H-J, Jeon BS, Lee J-Y, Yun JY: Survival of Korean patients with multiple system atrophy. Mov Disord 2011; 26: 909–912.
[PubMed]
https://doi.org/10.1002/mds.23580
26.
Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT: Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson’s disease. Mov Disord 2007; 22: 1917–1921.
[PubMed]
https://doi.org/10.1002/mds.21625
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.